Reykjavik / Isafjordur, May 23, 2014 – Kerecis Limited, the emerging leader in tissue-regeneration materials, will participate in the NASDAQ OMX Iceland Prospect Conference on Tuesday, May 27, at 2:15 pm. The conference will take place in the Harpa Conference Centre in Reykjavik, Iceland.
The NASDAQ OMX conference will connect Kerecis and 10 other early-stage companies with corporate investors. The conference is a part of NASDAQ OMX’s effort to support financial growth and help entrepreneurs get the funding they need.
Kerecis is the developer of the Kerecis Omega3 fish-skin regenerative surgical materials for multiple indications, including treatment of wounds and breast reconstruction. The first Kerecis product, Kerecis Omega3 Wound, is already on the market and is indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds. Materials indicated for hernia and dura repair are also under development.
When inserted into or onto damaged human tissue, the Kerecis Omega3 products recruit the body’s own cells, are incorporated into the wound, and ultimately are converted into functional, living tissue.
G. Fertram Sigurjonsson, Founder and CEO of Kerecis
“As our business advances we are happy to share our progress with the customers of NASDAQ OMX. We are making good progress in developing our technology beyond its currently approved use as a treatment for chronic wounds. Our goal is to develop a procedurally integrated platform that could potentially transform how tissue damage is treated across multiple indications, such as hernia repair, breast reconstruction and dura repair.”